Unknown

Dataset Information

0

Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model.


ABSTRACT: AZD9291 (osimertinib) is approved for standard care in patients with EGFR T790M-positive non-small cell lung cancer (NSCLC) after prior EGFR TKI progression. Furthermore, AZD9291 is now being evaluated as a first-line treatment for NSCLC patients with activation EGFR mutations. Based on previous experiments, resistance to AZD9291 as a first-line treatment may also emerge. Thus, identification and understanding of resistance mechanisms to AZD9291 as a first-line treatment can help direct development of future therapies. AZD9291-resistant cells (PC9/AZDR) were established using EGFR inhibitor-naïve PC9 cells. Resistance mechanisms were analyzed using next-generation sequencing (NGS) and a proteome profiler array. Resistance to AZD9291 developed through aberrant activation of ERK signaling by an EGFR-independent mechanism. The combination of a MEK inhibitor with AZD9291 restored the sensitivity of PC9/AZDR cells in vitro and in vivo. PC9/AZDR cells also showed increased MET expression and an HRAS G13R mutation. In addition, maspin expression was higher after AZD9291 treatment in PC9/AZDR cells. Sustained ERK activation confers resistance to AZD9291 as a first-line therapy. Thus, co-targeting EGFR and MEK may be an effective strategy to overcome resistance to AZD9291.

SUBMITTER: Ku BM 

PROVIDER: S-EPMC5895014 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

altmetric image

Publications

Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model.

Ku Bo Mi BM   Choi Moon Ki MK   Sun Jong-Mu JM   Lee Se-Hoon SH   Ahn Jin Seok JS   Park Keunchil K   Ahn Myung-Ju MJ  

PloS one 20180411 4


AZD9291 (osimertinib) is approved for standard care in patients with EGFR T790M-positive non-small cell lung cancer (NSCLC) after prior EGFR TKI progression. Furthermore, AZD9291 is now being evaluated as a first-line treatment for NSCLC patients with activation EGFR mutations. Based on previous experiments, resistance to AZD9291 as a first-line treatment may also emerge. Thus, identification and understanding of resistance mechanisms to AZD9291 as a first-line treatment can help direct developm  ...[more]

Similar Datasets

| S-EPMC4605607 | biostudies-literature
| S-EPMC5668147 | biostudies-literature
| S-EPMC6533774 | biostudies-literature
2015-04-14 | E-GEOD-59239 | biostudies-arrayexpress
2015-04-14 | GSE59239 | GEO
| S-EPMC6396678 | biostudies-literature
| S-EPMC4771182 | biostudies-literature
| S-EPMC7872905 | biostudies-literature
| S-EPMC2518074 | biostudies-literature